Bausch Health Companies Inc. (BHC) Stock Analysis and Metrics

Bausch Health Companies

NYSE: BHC

$4.43 ▼ -0.01 (-0.34%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.65 Bn

P/E-1.34

P/S0.16

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)21.65 Bn

Revenue Growth (1y) (Qtr)11.73

Add ratio to table…

About

Bausch Health Companies Inc. is a global diversified specialty pharmaceutical and medical device company that develops manufactures and markets branded generic and over the counter products as well as aesthetic medical devices primarily in the therapeutic areas of gastroenterology hepatology neuroscience and dermatology and through its approximately 87 % ownership of Bausch + Lomb Corporation also offers vision care surgical and pharmaceutical products in the eye health space. The company markets its products directly or indirectly in approximately 90 countries worldwide.

Revenue is generated principally from product sales that include branded pharmaceuticals generic and branded generic pharmaceuticals over the counter items and medical devices such as contact lenses intraocular lenses ophthalmic surgical equipment and aesthetic devices. Additional revenue comes from alliance and service revenues related to licensing promotion and contract manufacturing activities.

The company operates through the following segments: Salix International Solta Medical Diversified and Bausch + Lomb.

• Salix: This segment consists of sales in the United States of gastrointestinal products with the Xifaxan® product line representing roughly 85 % of its revenues.

• International: This segment comprises sales outside the United States of branded pharmaceutical branded generic and over the counter products excluding Bausch + Lomb and Solta Medical offerings.

• Solta Medical: This segment covers global sales of Solta Medical aesthetic medical devices including laser‑based skin resurfacing systems.

• Diversified: This segment includes United States sales of neuroscience dermatology generic and dentistry pharmaceutical products.

• Bausch + Lomb: This segment encompasses global sales of Bausch + Lomb Vision Care Surgical and Pharmaceuticals products such as contact lenses intraocular lenses ophthalmic surgical equipment and eye health pharmaceuticals.

Within its core therapeutic areas the company holds leading positions in gastroenterology hepatology dermatology neuroscience international pharmaceuticals and aesthetic medical devices while Bausch + Lomb is a fully integrated eye health company built on an iconic brand giving it a competitive advantage through broad product diversification strong brand recognition and a global footprint spanning roughly 90 countries.

The company serves patients healthcare providers pharmacies wholesalers and retail chains with specific customers including Walgreens through fulfillment arrangements for dermatology products and patients accessing its products via prescriptions over the counter purchases and medical device channels.

Investment Thesis

▲ Bull case

Bausch Health Companies Inc. (BHC) is demonstrating resilient operational momentum with twelve consecutive quarters of year-over-year revenue and adjusted EBITDA growth in its core business excluding Bausch and Lomb, driven by strong performance in Salix and Solta Medical segments. Salix reported 18% revenue growth in Q1 FY26, led by XIFAXAN's 21% increase, supported by healthy prescription trends and residual volume benefits from exited channels, while Solta achieved 51% reported revenue growth and 19% organic growth, fueled by 193% year-over-year growth in China following the Xibo acquisition, which has enhanced vertical integration, improved demand forecasting, and unlocked pricing power in a market with durable demand for capital and consumables equipment. This underlying strength is being amplified by strategic investments in AI-enabled commercial tools, which have already delivered a 20% surge in sales productivity for XIFAXAN and enabled nearly 700 thousand new patient starts, with early data suggesting a 20%+ lift in new prescriptions for other U.S. pharmaceutical brands, creating a scalable competitive advantage in field force effectiveness and R&D efficiency through AI-driven site selection, pharmacovigilance, and indication selection.
The company's capital structure optimization is progressing steadily, with net debt excluding Bausch and Lomb decreasing by approximately $115 million in Q1 FY26 after $160 million in legacy litigation outflows, and full-year 2026 guidance for adjusted EBITDA growth of 4% at the midpoint already incorporates the anticipated impact of new tariffs effective September 2026, signaling management's confidence in absorbing macroeconomic headwinds without compromising profitability. Furthermore, BHC is actively evaluating business development opportunities in late-stage or commercial-ready assets aligned with its expertise in GI, hepatology, neurosciences, and anesthetics, leveraging its proven commercial execution to accelerate value creation, while maintaining flexibility to raise equity capital for tuck-in investments, as indicated by CFO Jean-Jacques Charhon's openness to enhancing financial flexibility through market access when strategically advantageous.
Beyond core operations, Bausch and Lomb's recent innovations—including the European launch of the Bi-Blade+ vitrectomy cutter with 62% reduced vibration and 25% higher flow rate, and the U.S. launch of PreserVision AREDS3 eye vitamins incorporating a B-vitamin complex backed by two decades of research linking B vitamins to reduced AMD risk—are expanding addressable markets and reinforcing the segment's leadership in surgical and consumer eye health, with Thermage® earning the AAA Well-Known Trademark Certification in China, a rare accolade held by only 217 brands nationwide, validating its market influence and consumer trust in a core aesthetics franchise. These developments, combined with the reaffirmed full-year guidance and continued shareholder support—evidenced by the election of all ten director nominees at the 2026 Annual Meeting—underscore a balanced execution of value creation across both the pharmaceutical and eye health arms of the business, positioning BHC for sustained long-term growth beyond near-term XIFAXAN exclusivity concerns.

Bausch Health Companies Inc. (BHC) is demonstrating resilient operational momentum with twelve consecutive quarters of year-over-year revenue and adjusted EBITDA growth in its core business excluding Bausch and Lomb, driven by strong performance in Salix and Solta Medical segments. Salix reported 18% revenue growth in Q1 FY26, led by XIFAXAN's 21% increase, supported by healthy prescription trends and residual volume benefits from exited channels, while Solta achieved 51% reported revenue growth and 19% organic growth, fueled by 193% year-over-year growth in China following the Xibo acquisition, which has enhanced vertical integration, improved demand forecasting, and unlocked pricing power in a market with durable demand for capital and consumables equipment. This underlying strength is being amplified by strategic investments in AI-enabled commercial tools, which have already delivered a 20% surge in sales productivity for XIFAXAN and enabled nearly 700 thousand new patient starts, with early data suggesting a 20%+ lift in new prescriptions for other U.S. pharmaceutical brands, creating a scalable competitive advantage in field force effectiveness and R&D efficiency through AI-driven site selection, pharmacovigilance, and indication selection.
The company's capital structure optimization is progressing steadily, with net debt excluding Bausch and Lomb decreasing by approximately $115 million in Q1 FY26 after $160 million in legacy litigation outflows, and full-year 2026 guidance for adjusted EBITDA growth of 4% at the midpoint already incorporates the anticipated impact of new tariffs effective September 2026, signaling management's confidence in absorbing macroeconomic headwinds without compromising profitability. Furthermore, BHC is actively evaluating business development opportunities in late-stage or commercial-ready assets aligned with its expertise in GI, hepatology, neurosciences, and anesthetics, leveraging its proven commercial execution to accelerate value creation, while maintaining flexibility to raise equity capital for tuck-in investments, as indicated by CFO Jean-Jacques Charhon's openness to enhancing financial flexibility through market access when strategically advantageous.
Beyond core operations, Bausch and Lomb's recent innovations—including the European launch of the Bi-Blade+ vitrectomy cutter with 62% reduced vibration and 25% higher flow rate, and the U.S. launch of PreserVision AREDS3 eye vitamins incorporating a B-vitamin complex backed by two decades of research linking B vitamins to reduced AMD risk—are expanding addressable markets and reinforcing the segment's leadership in surgical and consumer eye health, with Thermage® earning the AAA Well-Known Trademark Certification in China, a rare accolade held by only 217 brands nationwide, validating its market influence and consumer trust in a core aesthetics franchise. These developments, combined with the reaffirmed full-year guidance and continued shareholder support—evidenced by the election of all ten director nominees at the 2026 Annual Meeting—underscore a balanced execution of value creation across both the pharmaceutical and eye health arms of the business, positioning BHC for sustained long-term growth beyond near-term XIFAXAN exclusivity concerns.

▼ Bear case

Bausch Health Companies Inc. (BHC) faces significant near-term revenue pressure from the impending loss of XIFAXAN exclusivity on January 1, 2028, with Teva having secured final FDA approval as the first filer, and while management expresses confidence in its IP and contingency planning, the CFO acknowledged that an earlier-than-expected generic entrance would curtail free cash flow generation between now and 2027, necessitating earlier asset monetization and undermining the capital structure optimization strategy that relies on three variables: free cash flow through 2027, post-LOE EBITDA, and proceeds from monetizing the Bausch and Lomb equity stake, creating a precarious dependency on maintaining exclusivity until the target date.
Despite strong reported growth in Solta Medical, particularly in China, the segment's Q1 FY26 performance was inflated by the $32 million acquisition impact from Xibo, with organic growth at a more modest 19%, and the company acknowledged that segment profit was impacted by residual higher inventory costs from the integration, suggesting that the rapid revenue expansion may be coming at the expense of margin sustainability, especially as the company continues to invest in go-to-market efforts to sustain momentum in a market where demand, while currently insulated from broader macroeconomics, could face headwinds if consumer confidence weakens or if pricing power proves less durable than anticipated amid rising competition in the aesthetics space.
The Diversified segment continues to deteriorate, with Q1 FY26 revenue declining 10% on both reported and organic bases, driven by volume declines in the Neuroscience business partially offset by favorable pricing, a trend that reflects broader challenges in maintaining traction in non-core legacy portfolios, and while management cites favorable pricing as a mitigant, this strategy is inherently limited and risks accelerating volume erosion if price increases are not sustainable, raising concerns about the segment's long-term viability and its drag on overall portfolio performance, particularly as the company shifts focus toward higher-growth areas like GI and aesthetics.
Furthermore, BHC's guidance for full-year 2026 adjusted EBITDA growth of 4% at the midpoint implies a meaningful deceleration from the 17% year-over-year increase in Q1, suggesting that the strong start to the year may not be sustainable throughout the remainder of 2026, especially as the company anticipates impacts from its exit from Medicaid and 340B channels affecting Salix and Diversified segments in the back half of the year, and while AI investments show promise, their full-scale impact on sales productivity and R&D efficiency remains early-stage and unproven at scale, creating uncertainty about whether these initiatives can offset structural headwinds in key franchises.

Bausch Health Companies Inc. (BHC) faces significant near-term revenue pressure from the impending loss of XIFAXAN exclusivity on January 1, 2028, with Teva having secured final FDA approval as the first filer, and while management expresses confidence in its IP and contingency planning, the CFO acknowledged that an earlier-than-expected generic entrance would curtail free cash flow generation between now and 2027, necessitating earlier asset monetization and undermining the capital structure optimization strategy that relies on three variables: free cash flow through 2027, post-LOE EBITDA, and proceeds from monetizing the Bausch and Lomb equity stake, creating a precarious dependency on maintaining exclusivity until the target date.
Despite strong reported growth in Solta Medical, particularly in China, the segment's Q1 FY26 performance was inflated by the $32 million acquisition impact from Xibo, with organic growth at a more modest 19%, and the company acknowledged that segment profit was impacted by residual higher inventory costs from the integration, suggesting that the rapid revenue expansion may be coming at the expense of margin sustainability, especially as the company continues to invest in go-to-market efforts to sustain momentum in a market where demand, while currently insulated from broader macroeconomics, could face headwinds if consumer confidence weakens or if pricing power proves less durable than anticipated amid rising competition in the aesthetics space.
The Diversified segment continues to deteriorate, with Q1 FY26 revenue declining 10% on both reported and organic bases, driven by volume declines in the Neuroscience business partially offset by favorable pricing, a trend that reflects broader challenges in maintaining traction in non-core legacy portfolios, and while management cites favorable pricing as a mitigant, this strategy is inherently limited and risks accelerating volume erosion if price increases are not sustainable, raising concerns about the segment's long-term viability and its drag on overall portfolio performance, particularly as the company shifts focus toward higher-growth areas like GI and aesthetics.
Furthermore, BHC's guidance for full-year 2026 adjusted EBITDA growth of 4% at the midpoint implies a meaningful deceleration from the 17% year-over-year increase in Q1, suggesting that the strong start to the year may not be sustainable throughout the remainder of 2026, especially as the company anticipates impacts from its exit from Medicaid and 340B channels affecting Salix and Diversified segments in the back half of the year, and while AI investments show promise, their full-scale impact on sales productivity and R&D efficiency remains early-stage and unproven at scale, creating uncertainty about whether these initiatives can offset structural headwinds in key franchises.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password